Precision BioSciences (DTIL) Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Precision BioSciences in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" DTIL shares.
View DTIL analyst ratings or view top-rated stocks.

3 brokerages have issued 12-month price targets for Precision BioSciences' stock. Their DTIL share price forecasts range from $2.00 to $4.00. On average, they anticipate the company's share price to reach $3.00 in the next year. This suggests a possible upside of 699.4% from the stock's current price.
View analysts price targets for DTIL or view top-rated stocks among Wall Street analysts.

Precision BioSciences' stock was trading at $1.19 at the beginning of the year. Since then, DTIL shares have decreased by 68.5% and is now trading at $0.3753.
View the best growth stocks for 2023 here.

Precision BioSciences saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 1,640,000 shares, an increase of 62.4% from the August 15th total of 1,010,000 shares. Based on an average trading volume of 1,120,000 shares, the short-interest ratio is presently 1.5 days. Approximately 1.8% of the company's shares are short sold.
View Precision BioSciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our DTIL earnings forecast.

Precision BioSciences, Inc. (NASDAQ:DTIL) issued its earnings results on Friday, August, 4th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.13. The company had revenue of $19.79 million for the quarter, compared to analyst estimates of $6.58 million. Precision BioSciences had a negative trailing twelve-month return on equity of 163.24% and a negative net margin of 192.10%.

Kelly CRISPR & Gene Editing Technology ETF holds 133,661 shares of DTIL stock, representing 2.96% of its portfolio.

12 employees have rated Precision BioSciences Chief Executive Officer Matt Kane on Glassdoor.com. Matt Kane has an approval rating of 100% among the company's employees. This puts Matt Kane in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Precision BioSciences investors own include Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), Alector (ALEC), Kaleido Biosciences (KLDO), Gossamer Bio (GOSS), Micron Technology (MU), Homology Medicines (FIXX), Heron Therapeutics (HRTX), Inovio Pharmaceuticals (INO) and Invitae (NVTA).

(DTIL) raised $126 million in an initial public offering on Thursday, March 28th 2019. The company issued 7,900,000 shares at $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs, Jefferies and Barclays acted as the underwriters for the IPO.

Precision BioSciences trades on the NASDAQ under the ticker symbol "DTIL."

Precision BioSciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Great Point Partners LLC (6.49%), JPMorgan Chase & Co. (1.81%), Stifel Financial Corp (1.70%), Renaissance Technologies LLC (1.49%), CHI Advisors LLC (1.39%) and BlackRock Inc. (1.06%). Insiders that own company stock include Alan List, Dario Scimeca, David S Thomson, David S Thomson, Derek Jantz, John Alexander Kelly, Matthew R Kane, Matthew R Kane, Michael Amoroso and Vince Craig Hopkin.
View institutional ownership trends.

Shares of DTIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DTIL stock can currently be purchased for approximately $0.38.

Precision BioSciences (NASDAQ:DTIL) has a market capitalization of $43.19 million and generates $25.10 million in revenue each year. The company earns $-111,640,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis.

The company employs 192 workers across the globe.

Precision BioSciences' mailing address is 302 EAST PETTIGREW STREET SUITE A-100, DURHAM NC, 27701. The official website for the company is www.precisionbiosciences.com. The company can be reached via phone at (919) 314-5512 or via email at jwong@bplifescience.com.